Page 10 - Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update

Nickel et al

65. Bouza C, Lopez T, Magro A, et al. Systematic review and meta-analysis of transurethral needle ablation 78. Shim SR, Kanhai KJ, Ko YM, et al. Efficacy and safety of prostatic arterial embolization: Systematic
in symptomatic benign prostatic hyperplasia. BMC Urol 2006;6:14. https://doi.org/10.1186/1471- review with meta-analysis and meta-regression. J Urol 2017;197:465-79. https://doi.org/10.1016/j.
2490-6-14 juro.2016.08.100
66. Vanderbrink BA, Rastinehad AR, Badlani G. Prostatic stents for the treatment of benign prostatic hyperplasia. 79. Russo GI, Kurbatov D, Sansalone S, et al. Prostatic arterial embolization vs. open prostatectomy: A one-
Curr Opin Urol 2007;17:1-6. https://doi.org/10.1097/MOU.0b013e3280117747 year matched-pair analysis of functional outcomes and morbidities. Urology 2015;86:343-8. https://
67. Senksen J, Barber NJ, Speakman, MJ et al. Prospective, randomized, multinational study of prostatic doi.org/10.1016/j.urology.2015.04.037
urethral lift vs. transurethral resection of the prostate: 12-month results from the BPH6 study. Eur Urol 80. Lucas MG, Stephenson TP, Nargund V. Tamsulosin in the management of patients in acute urinary
2015;68:643-52. https://doi.org/10.1016/j.eururo.2015.04.024 retention from benign prostatic hyperplasia. BJU Int 2005;95:354-7. https://doi.org/10.1111/j.1464-
68. Roehrborn CG, Barkin J, Gange SN, et al. Five-year results of the prospective, randomized controlled 410X.2005.05299.x
prostatic urethral L.I.F.T. study. Can J Urol 2017;24:8802-13. 81. McNeill SA, Hargreave TB, Roehrborn CG; Alfaur study group. Alfuzosin 10 mg once daily in the manage-
69. McVary KT, Gange SN, Gittelman MC, et al. Minimally invasive prostate convective water vapour energy ment of acute urinary retention: Results of a double-blind, placebo-controlled study. Urology 2005;65:83-9.
ablation: A multicentre, randomized controlled study for the treatment of lower urinary tract symptoms https://doi.org/10.1016/j.urology.2004.07.042
secondary to benign prostatic hyperplasia. J Urol 2016;195:1529-38. https://doi.org/10.1016/j. 82. Patel SB, Ranka K, Kundargi VS, et al. Comparison of tamsulosin and silodosin in the management of
juro.2015.10.181 acute urinary retention secondary to benign prostatic hyperplasia in patients planned for trial without
70. McVary KT, Gange SN, Gittelman MC, et al. Erectile and ejaculatory function preserved with convec-Erectile and ejaculatory function preserved with convec- catheter. A prospective, randomized study. Cent European J Urol 2017;70:259-63.
tive water vapour energy treatment of lower urinary tract symptoms secondary to benign prostatic 83. Abrams P, Cardozo L, Fall M, et al. The standardization of terminology of lower urinary tract function:
hyperplasia: Randomized controlled study. J Sex Med 2016;13:924-33. https://doi.org/10.1016/j. Report from the Standardization Sub-committee of the International Continence Society. Neurourol Urodyn
jsxm.2016.03.372 2002;21:167-78. https://doi.org/10.1002/nau.10052
71. Roehrborn CG, Gange SN, Gittelman MC, et al. Convective radiofrequency water vapour thermal therapy 84. Chapple CR, Osman NI, Birder L, et al. The underactive bladder: A new clinical concept? Eur Urol
with rezum system: Durable two-year results of randomized controlled and prospective crossover studies for 2015;68:351-3. https://doi.org/10.1016/j.eururo.2015.02.030
treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. J Urol 2017;197:1507-16. 85. Potts B, Belsante M, Peterson A, et al. Bladder outlet procedures are an effective treatment for patients with
https://doi.org/10.1016/j.juro.2016.12.045 urodynamically confirmed detrusor underactivity without bladder outlet obstruction. J Urol 2016;195:e975.
72. Gilling P, Anderson P, Tan A. Aquablation of the prostate for symptomatic benign prostatic hyperplasia: https://doi.org/10.1016/j.juro.2016.02.1712
One-year results. J Urol 2017;197:1565-72. https://doi.org/10.1016/j.juro.2017.01.056 86. Delakas D, Lianos E, Karyotis I, et al. Finasteride: A long-term followup in the treatment of
73. Gilling P, Barner N, Bidair M, et al. WATER: A double-blind, randomized controlled trial of aquablation recurrent hematuria associated with benign prostatic hyperplasia. Urol Int 2001;67:69-72.
vs. transurethral resection of the prostate in benign prostatic hyperplasia. J Urol 2018;199:1252-61. https://doi.org/10.1159/000050948
https://doi.org/10.1016/j.juro.2017.12.065 87. Thompson IN, Goodman PJ, Tangen CM, et al. The influence of finasteride in the development of prostate
74. Porpiglia F, Fiori C, Bertolo R, et al. Temporary implantable nitinol device (TIND): A novel, minimally cancer. N Engl J Med 2003;349:211-20. https://doi.org/10.1056/NEJMoa030660
invasive treatment for relief of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia 88. Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl
(BPH): Feasibility, safety, and functional results at one year of followup. BJU Int 2015;116:278-87. J Med 2010;362:1192-202. https://doi.org/10.1056/NEJMoa0908127
https://doi.org/10.1111/bju.12982 89. Grubb RL, Andriole G, Sommerville MC, et al. The REDUCE followup study: Low rate of new prostate cancer
75. Pisco JM, Rio Tinto H, et al. Embolization of prostatic arteries as treatment of moderate to severe lower diagnosis observed during a two-year, observational followup study of men who participated in the REDUCE
urinary symptoms (LUTS) secondary to benign hyperplasia: Results of short- and midterm followup. Eur trial. J Urol 2013;189:871-977. https://doi.org/10.1016/j.juro.2012.09.099
Radiol 2013;23:2561-72. https://doi.org/10.1007/s00330-012-2714-9 90. Klotz L, Chetner M, Chin J, et al. Canadian consensus conference: The FDA decision on the use of 5ARIs.
76. Carnevale FC, Iscaife A, Yoshinaga EM, et al. Transurethral resection of the prostate (TURP) versus Can Urol Assoc J 2012;6:83-8. https://doi.org/10.5489/cuaj.12058
original and PErFecTED prostate artery embolization (PAE) due to benign prostatic hyperplasia (bph):
Preliminary results of a single-centre, prospective, urodynamic-controlled analysis. Cardiovasc Intervent Correspondence: Dr. J. Curtis Nickel, Department of Urology, Queen’s University, Kingston, ON,
Radiol 2016;39:44-52. https://doi.org/10.1007/s00270-015-1202-4 Canada; jcn@queensu.ca
77. Gao YA, Huang Y, Zhang R, et al. Benign prostatic hyperplasia: Prostatic arterial embolization vs. trans-Benign prostatic hyperplasia: Prostatic arterial embolization vs. trans-
urethral resection of the prostate — a prospective, randomized, and controlled clinical trial. Radiology
2014;270:920-8. https://doi.org/10.1148/radiol.13122803

312 CUAJ • October 2018 • Volume 12, Issue 10